NCT01431209View on ClinicalTrials.gov

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 12, 2011

Primary Completion Date

October 28, 2020

Study Completion Date

May 26, 2021

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (3)

20892

National Institutes of Health Clinical Center, Bethesda

55905

Mayo Clinic, Rochester

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT01431209 - Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant | Biotech Hunter | Biotech Hunter